Research Topics
Species | James J DignamSummaryAffiliation: University of Chicago Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
The use and interpretation of competing risks regression modelsJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 18:2301-8. 2012..With competing risks, several modeling approaches are available to evaluate the relationship of covariates to cause-specific failures. We discuss the use and interpretation of commonly used competing risks regression models...
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancerJames J Dignam
Department of Health Studies, 5841 South Maryland Ave, MC 2007, University of Chicago, Chicago, IL 60637, USA
J Natl Cancer Inst 98:1647-54. 2006..We investigated the association of body mass index (BMI) with outcomes after colon cancer in patients from cooperative group clinical trials...- Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancerJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
Breast Cancer Res Treat 97:245-54. 2006..Both obesity and estrogen receptor negative (ER-) tumors are more prevalent in black women than in whites in North America. We evaluated obesity and race in relation to outcomes in women with ER-breast cancer... - Choice and interpretation of statistical tests used when competing risks are presentJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
J Clin Oncol 26:4027-34. 2008..We present simulation study results and discuss examples from cancer clinical trials to illustrate these points and provide guidance for analysis when competing risks are present... - Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancerJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
Breast Cancer Res Treat 116:595-602. 2009..Examination of the magnitude and changes in the hazard of failure over time in node-negative breast cancer may also be informative in this regard... - Estimating breast cancer-specific and other-cause mortality in clinical trial and population-based cancer registry cohortsJames J Dignam
Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
Cancer 115:5272-83. 2009..The authors of this report evaluated the performance of these estimates relative to a third approach based on detailed clinical follow-up history... - The role of cancer cooperative groups within the spectrum of cancer careJames J Dignam
Department of Health Studies, The University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
Cancer Control 11:55-63. 2004 - Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancerJames J Dignam
Department of Health Studies and Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
J Natl Cancer Inst 95:1467-76. 2003..We evaluated the association of obesity with outcomes and with tamoxifen efficacy in women with early-stage, hormone-responsive breast cancer participating in a multicenter cancer cooperative group clinical trial... - Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trialsJames J Dignam
Department of Health Studies, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637, USA
J Clin Oncol 21:413-20. 2003..The randomized trial setting enhances uniformity in disease stage and treatment plan among all participants... - A missing data approach to semi-competing risks problemsJames J Dignam
Department of Health Studies, The University of Chicago, Chicago, IL 60637, USA
Stat Med 26:837-56. 2007..We apply the proposed method to the problem of estimating the distribution of time to tumour recurrence at specific sites among breast cancer patients participating in randomized clinical trials... 
Race and the prognostic influence of p53 in women with breast cancerKeith A Dookeran
The Cancer Foundation for Minority and Underserved Populations, Chicago, IL, USA
Ann Surg Oncol 19:2334-44. 2012..We investigate whether the influence of p53 is unique to AAs or is present in other race/ethnic groups, and how this compares with known prognostic factors...- Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriersAngela R Bradbury
University of Chicago Center for Clinical Cancer Genetics, University of Chicago, Chicago, Illinois, USA
Genet Med 10:161-6. 2008..To evaluate prophylactic salpingo-oophorectomy uptake and timing among BRCA1/2 mutation carriers in a cancer risk assessment program... - p53 as a marker of prognosis in African-American women with breast cancerKeith A Dookeran
The Cancer Foundation for Minority and Underserved Populations, Chicago, IL, USA
Ann Surg Oncol 17:1398-405. 2010..We investigate the value of p53 status within the context of stage and intrinsic subtype classification (subtype), in a group of African-American (AA) women of lower socioeconomic status (SES) with primary breast cancer... - Colorectal cancer model of health disparities: understanding mortality differences in minority populationsBlase N Polite
Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
J Clin Oncol 24:2179-87. 2006..Finally, areas of ongoing and future research and policy initiatives aimed at reducing disparities are discussed... - Lung volume measurements as a surrogate marker for patient response in malignant pleural mesotheliomaZacariah E Labby
Department of Radiology, The University of Chicago, Chicago, IL 60637, USA
J Thorac Oncol 8:478-86. 2013..Linear tumor thickness measurements, disease volume measurements, and lung volume measurements (a physiological correlate of disease volumes) were investigated in this study... - Colorectal cancer and race: understanding the differences in outcomes between African Americans and whitesBlase N Polite
Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
Med Clin North Am 89:771-93. 2005..The task now becomes to continue to understand the reasons for the disparities and ultimately to come up with workable solutions so that the amazing progress in CRC treatment benefits all groups in this country... - Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerEzra E W Cohen
Department of Medicine, University of Chicago, Chicago, IL, USA
J Clin Oncol 28:3336-43. 2010.... - Optimization of response classification criteria for patients with malignant pleural mesotheliomaZacariah E Labby
Department of Radiology, The University of Chicago, Chicago, IL 60637, USA
J Thorac Oncol 7:1728-34. 2012..The purpose of this work is to optimize the correlation between tumor response and patient survival by assessing the validity of existing response criteria in MPM and proposing alternative criteria... - How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adultsAngela R Bradbury
Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
J Clin Oncol 25:3705-11. 2007..Yet, many BRCA mutation carriers discuss their results with their children. This study describes the prevalence and experiences of parental communication of BRCA results to children under the age of 25 years old... - Is patient travel distance associated with survival on phase II clinical trials in oncology?Elizabeth B Lamont
Department of Medicine and Cancer Research Center, The University of Chicago, Chicago, IL, USA
J Natl Cancer Inst 95:1370-5. 2003..We hypothesized that this phenomenon, often called "referral bias" or "distance bias," may also be evident in curative-intent cancer trials at specialized cancer centers... - MYC is amplified in BRCA1-associated breast cancersTatyana A Grushko
Section of Hematology Oncology, Department of Medicine, Committees on Genetics and Cancer Biology, University of Chicago, Chicago, Illinois 60637 1463, USA
Clin Cancer Res 10:499-507. 2004.... - Diffusing capacity predicts long-term survival after lung resection for cancerMark K Ferguson
Department of Surgery, The University of Chicago, Chicago, IL, USA
Eur J Cardiothorac Surg 41:e81-6. 2012..Diffusing capacity (DLCO) is a predictor of complications after resection for lung cancer. We sought to determine whether DLCO is also prognostic for long-term survival after lung resection for cancer... - Semiparametric models for cumulative incidence functionsJohn Bryant
Departments of Biostatistics and Statistics, University of Pittsburgh and National Surgical Adjuvant Breast and Bowel Project, 201 N Craig Street, Suite 350, Pittsburgh, Pennsylvania 15213, USA
Biometrics 60:182-90. 2004..More surprisingly, they are often nearly as efficient as fully parametric estimators. We illustrate the utility of this approach in the analysis of patients treated for early stage breast cancer... - Mammographic density and breast cancer after ductal carcinoma in situLaurel A Habel
Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94612, USA
J Natl Cancer Inst 96:1467-72. 2004..Our results provide initial evidence that the risk of second breast cancers may be increased among DCIS patients with highly dense breasts... - The ongoing search for the sources of the breast cancer survival disparityJames J Dignam
J Clin Oncol 24:1326-8. 2006 - Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or lessBernard Fisher
National Surgical Adjuvant Breast and Bowel Project Biostatistical Center, Division of Pathology, and Breast Committee, Pittsburgh, PA, USA
J Clin Oncol 20:4141-9. 2002.... - Early viewing of noninferiority trials in progressJames J Dignam
J Clin Oncol 23:5461-3. 2005 - Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessmentMichael J Hall
Department of Medicine, Columbia University College of Physicians and Surgeons, Mailman School of Public Health, New York, NY 10032, USA
J Genet Couns 17:365-72. 2008..In risk assessment for HBOS, identifying a family history of PC should strongly raise the suspicion of an unrecognized BRCA1/2 mutation...
Research Grants
- Obesity and Outcomes After Early Stage Breast CancerJames Dignam; Fiscal Year: 2003..These investigations will provide valuable information for current patient management and insights into appropriate prospective interventions to improve breast cancer survivorship. ..